Premium
Effects of puerarin on differentiation of 3T3‐L1 preadipocytes
Author(s) -
Lee OkHwan,
Seo DongHo,
Park CheonSeok,
Kim YoungCheul
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.716.15
Subject(s) - puerarin , glut4 , pueraria , adipocyte , endocrinology , adiponectin , medicine , 3t3 l1 , insulin resistance , glucose transporter , adipogenesis , glucose uptake , chemistry , oil red o , insulin , gene expression , biology , biochemistry , adipose tissue , gene , alternative medicine , pathology
Puerarin (daidzein 8‐C‐glucoside), a major isoflavone glycoside derived from Kudzu root ( Pueraria lobata ), has been shown to favorably affect glucose and lipid metabolism associated with insulin resistance, diabetes, and cardiovascular diseases. Here, we examined the effects of puerarin on the changes of key gene expression associated with adipocyte differentiation and insulin sensitivity using 3T3‐L1 cell, a cell line that undergoes differentiation into adipocytes in the presence of adipogenic hormonal stimuli. 3T3‐L1 preadipocytes were differentiated in the presence of various concentrations of Puerarin for up to 6 days, followed by Oil Red‐O staining of lipids and gene expression using semi‐quantitative RT‐PCR. Puerarin treatment significantly enhanced differentiation of 3T3‐L1 preadipocytes in a dose‐dependent manner. At day 6 after the differentiation, 100µM puerarin increased expression of PPARγ mRNA (~1.7‐fold) and its target gene adipocyte‐specific fatty acid binding protein (aP2) mRNA (~1.2‐fold). Puerarin treatment also up‐regulated the expression of GLUT4 and adiponectin mRNAs (~2.0‐fold and 1.7‐fold, respectively), two important genes for insulin sensitivity. These data indicate that the insulin‐sensitizing effects of puerarin may involve activation of PPARγ and stimulation of GLUT4 and adiponectin gene expression, leading to overall increased glucose utilization